ICAP
AC-20 - 胞浆细颗粒型
  简体中文 English
同义词 胞浆斑点型 cytoplasmic speckled
描述

细胞胞浆中呈现散在细小颗粒的染色,多具均匀或致密细颗粒的背景。例如抗Jo-1抗体。

Scattered small speckles in the cytoplasm mostly with homogeneous or dense fine speckled background. e.g. anti-Jo-1.

抗原相关性 Jo-1/组氨酰-tRNA合成酶 Jo-1/histidyl-tRNA synthetase
临床相关性
一级信息
关于临床相关性和缩写列表
Clinical Relevance
First level information
About Clinical Relevance & List of Abbreviations

►在抗合成酶抗体综合征 (自身免疫性肌病的一种)、间质性肺病、多发性关节炎、雷诺现象和技工手的患者中可检出;这些特征可能以多种形式或单一形式出现,尤其是间质性肺病 (33, 90)

►所报道的与AC-20核型相关的自身抗体主要为抗Jo-1抗体,该抗体识别组氨酰- tRNA合成酶;由于AC-20不是Jo-1抗体的特异核型,因此推荐后续检测抗Jo-1特异性抗体;抗原包含于常规 ENA 谱和疾病特异性免疫试剂 (即肌炎谱 *)中;抗Jo-1抗体已被纳入自身免疫性肌病分类标准中 (91, 92)

注:AC-19和AC-20之间的细微区别可能取决于HEp-2细胞底物和/或抗体浓度;在HEp-2细胞的间接免疫荧光筛查中可能检测不到针对Jo-1的抗体。

*肌炎谱、系统性硬化症谱和 (扩展的) 肝病谱可能仅限于专业临床实验室应用。


► Found in patients with the anti-synthetase syndrome (a subset of AIM), interstitial lung disease, polyarthritis, Raynaud’s phenomenon, and mechanic’s hands; these features may occur in various combinations or as an isolated manifestation, especially interstitial lung disease (33, 90)

► Autoantibodies associated with the AC-20 pattern are primarily reported for the anti-Jo-1 antibody, which recognizes histidyl-tRNA synthetase; since AC-20 is not specific for Jo-1, it is recommended to perform a follow-up test for anti-Jo-1 antibodies; the antigen is included in the routine ENA profile, as well as in disease specific immunoassays (i.e., inflammatory myopathy profile*); the anti-Jo-1 antibodies are included in the classification criteria for AIM (91, 92)

Notes: The fine distinction between AC-19 and -20 may depend on HEp-2 substrates and/or antibody concentration; antibodies to Jo-1 may be undetected in HEp-2 IIFA-screening.

*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.


一级信息参考文献 First level information references

33. Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52:1–19.

90. Marie I, Hatron PY, Cherin P, et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther 2013;15.

91. Fritzler MJ, Choi MY, Mahler M. The antinuclear antibody test in the diagnosis of antisynthetase syndrome and other autoimmune myopathies. J Rheumatol 2018;45:444.1–5.

92. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76:1955–64.

33. Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52:1–19.

90. Marie I, Hatron PY, Cherin P, et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther 2013;15.

91. Fritzler MJ, Choi MY, Mahler M. The antinuclear antibody test in the diagnosis of antisynthetase syndrome and other autoimmune myopathies. J Rheumatol 2018;45:444.1–5.

92. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76:1955–64.


二级信息 Second level information


None

二级信息参考文献 Second level information references


None

FAQ
No FAQ received
 
 

Online since 19 May 2015